The European market for abdominal aortic stent grafts will approach $300 million by 2015, according to the Millennium Research Group.

A report by the medtech market intelligence analyst notes that European doctors are increasingly using endovascular aortic repair (EVAR), rather than more invasive open surgery, to treat abdominal aortic aneurysms (AAAs).

The Endovascular versus Open Repair of AAA (EVAR-1) trial has established that long-term mortality rates for EVAR and open surgery are comparable, though EVAR has higher rates of re-intervention.

However, the shorter recovery times associated with EVAR are predicted to drive a rise in the number of aortic stent graft procedures performed each year in Europe to about 35,000 by 2015.

A number of new stent grafts from major medical device companies - such as Medtronic's Endurant device, Cook Medical's Zenith Fenestrated AAA Endovascular Graft and Gore's C3 Delivery System - are designed to overcome the limitations of older stent graft technologies such as migration, poor deliverability and failure to adjust to challenging anatomies.

"Competition in the European market for EVAR devices will increase over the next five years as new stent grafts by emerging competitors such as Aptus Endosystems and Cordis become available in addition to already-present products by other leading manufacturers such as Endologix, JOTEC and Terumo Medical," said Fareed Hameed, Analyst at MRG.

"The recent introduction of new devices will allow for more types of patients with AAA to be treated via EVAR."

Millennium Research Group is a leading global authority on medtech market intelligence.

 
Endurant stent graft

Share this article: